`
According to Fortune Business Insights, the global AI in genomics market size was valued at USD 1.36 billion in 2025 and is projected to grow from USD 1.56 billion in 2026 to USD 12.57 billion by 2034, registering a remarkable CAGR of 29.85% during the forecast period. North America dominated the market with a 45.59% share in 2025, driven by advanced healthcare infrastructure and strong AI adoption.
Artificial Intelligence (AI) in genomics involves using machine learning, deep learning, and advanced analytics to interpret DNA/RNA data and generate insights such as:
- Disease variant detection
- Treatment outcome prediction
- Drug target discovery
- Precision medicine applications
Key players include QIAGEN, NVIDIA Corporation, Illumina, Inc., and SOPHiA GENETICS, all focusing on advanced AI-driven genomics platforms and software innovation.
MARKET OVERVIEW
AI in genomics is rapidly transforming healthcare and life sciences by enabling:
- Faster genomic data interpretation
- Scalable analysis of multi-omics datasets
- Improved clinical decision-making
The market is strongly driven by:
- Explosion of sequencing data
- Integration of AI into healthcare workflows
- Growth in precision medicine and drug discovery
MARKET TRENDS
Shift Toward Cloud and Hybrid Deployment
A key trend shaping the market is the adoption of cloud and hybrid deployment models.
Key Benefits:
- Scalable compute power for large genomic datasets
- Faster analysis turnaround times
- Reduced infrastructure costs
- Improved collaboration across institutions
Hybrid models are gaining traction due to:
- Data privacy and regulatory requirements
- Need to keep sensitive genomic data on-premise
This trend is also driving:
- SaaS-based genomics platforms
- Recurring revenue models for vendors
- Faster onboarding and system upgrades
MARKET DYNAMICS
MARKET DRIVERS
Rapid Growth in Sequencing and Multi-Omics Data
The surge in genomic data generation is a primary growth driver:
- Increased sequencing throughput
- Expansion of multi-omics research
- Larger cohort-based studies
Impact:
- Manual analysis is no longer feasible
- Strong demand for AI-driven automation
- Increased adoption of scalable analytics platforms
AI enables:
- Variant detection and prioritization
- Integration of genomic, transcriptomic, and epigenomic data
- Faster and more accurate insights
Get Free Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/artificial-intelligence-in-genomics-market-107737
MARKET RESTRAINTS
Data Privacy and Regulatory Constraints
Genomic data is highly sensitive, leading to:
- Strict data privacy regulations
- Cross-border data transfer limitations
- Complex compliance requirements
Impact:
- Slower deployment cycles
- Increased operational costs
- Reduced data-sharing between institutions
MARKET OPPORTUNITIES
Government and Public Health Genomics Initiatives
Government-backed programs are creating strong opportunities:
- Population genomics projects
- Genomic surveillance systems
- Public health data platforms
Benefits:
- Stable and long-term funding
- Continuous data generation
- Increased adoption of AI platforms
These initiatives also support:
- Cross-border collaboration
- Large-scale longitudinal datasets
- Advanced outbreak detection and monitoring
MARKET CHALLENGES
Integration Complexity with Existing Systems
A major challenge is integrating AI solutions with:
- LIMS (Laboratory Information Management Systems)
- EMR/EHR systems
- Existing bioinformatics pipelines
Challenges include:
- Custom data mapping
- Workflow validation
- Regulatory compliance
This leads to:
- Longer implementation timelines
- Higher dependency on service providers
- Adoption barriers despite strong AI capabilities
SEGMENTATION ANALYSIS
By Component
- Software
- Services
Software dominates due to:
- Scalability across multiple sites
- Recurring revenue models
- Continuous upgrades and innovation
Services are growing rapidly (CAGR 26.83%) due to implementation and integration needs.
By Technology
- Machine learning
- Natural language processing (NLP)
Machine learning dominates as it powers:
- Variant detection
- Predictive modeling
- Biomarker discovery
NLP is fastest-growing (CAGR 32.79%), enabling:
- Clinical report interpretation
- Literature mining
- Automated insights generation
By Application
- Clinical diagnostics
- Drug discovery & development
- Population genomics
- Precision medicine
Clinical diagnostics dominates, driven by:
- Rising chronic disease prevalence
- Need for rapid diagnosis
- Increasing regulatory approvals
Drug discovery is a high-growth segment (CAGR 28.44%).
By Deployment
- Cloud-based
- On-premise
- Hybrid
Cloud-based deployment dominates due to:
- High scalability
- GPU acceleration for AI models
- Easier collaboration
Hybrid deployment is fastest-growing (CAGR 31.08%), balancing flexibility and compliance.
By End User
- Pharmaceutical & biotechnology companies
- Academic & research institutes
- Clinical labs & diagnostic centers
Pharma & biotech companies dominate due to:
- Continuous genomics workflows
- Large-scale data generation
- AI-driven drug discovery
Clinical labs are fastest-growing (CAGR 32.40%).
Get Free Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/artificial-intelligence-in-genomics-market-107737
REGIONAL OUTLOOK
North America
- Market size: USD 0.62 billion (2025)
Drivers:
- Strong genomics and pharma ecosystem
- High AI adoption
- Supportive government policies
U.S.
- ~41.1% global share (2026)
- Leading innovation hub
Europe
- CAGR: 29.58%
Drivers:
- Established genomics research infrastructure
- Growing AI investments
- Strong regulatory frameworks
Asia Pacific
- Rapidly growing region
- Market size: USD 0.31 billion (2026)
Drivers:
- Increasing sequencing adoption
- Expanding biotech sector
- Government investments
Key markets:
- China
- India
- Japan
Latin America & Middle East & Africa
- Moderate growth
Drivers:
- Expanding digital healthcare infrastructure
- Increasing AI adoption in healthcare
Key Players
- Illumina, Inc.
- QIAGEN
- SOPHiA GENETICS
- NVIDIA Corporation
- DNAnexus
- Fabric Genomics
- Tempus
- Velsera
KEY INDUSTRY DEVELOPMENTS
- Nov 2025: SOPHiA GENETICS partnered with Complete Genomics for AI-driven oncology solutions
- Sept 2025: SeqOne acquired Congenica to expand genomics AI capabilities
- July 2025: AWS HealthOmics enhanced workflow deployment capabilities
- June 2025: Velsera expanded its global clinico-genomic data network
- March 2025: Genomenon launched AI-powered genomic interpretation enhancements
KEY TAKEAWAY
The AI in genomics market is a high-growth, transformative sector (CAGR ~30%), driven by:
- Explosion of genomic and multi-omics data
- Rising adoption of AI in healthcare
- Growth in precision medicine and drug discovery
Despite challenges such as data privacy and integration complexity, the market is positioned for rapid expansion, with AI becoming a core enabler of next-generation genomics and personalized healthcare.
`
Top comments (0)